论文部分内容阅读
目的分析探讨酚妥拉明联合血管紧张素转换酶抑制剂(ACEI)在治疗婴幼儿重症肺炎合并心力衰竭方面的临床效果。方法选取2009年4月-2012年5月间在我院住院治疗的70例重症肺炎合并心力衰竭患儿,将其分为观察组和对照组各35例。对照组采用常规治疗措施,观察组在对照组基础上加用酚妥拉明与血管紧张素转换酶抑制剂卡托普利,比较两组的临床疗效。结果观察组用药24h后总有效率为91.4%,高于对照组的80.0%,组间差异有统计学意义(P<0.05);观察组患儿心衰纠正时间、症状缓解时间、肺部音消失时间以及总的住院时间均明显短于对照组患儿(P<0.05)。结论酚妥拉明联合ACEI在治疗婴幼儿重症肺炎合并心力衰竭方面疗效显著,患儿心衰症状改善明显,值得临床推广。
Objective To investigate the clinical effect of phentolamine combined with angiotensin-converting enzyme inhibitor (ACEI) in the treatment of infantile severe pneumonia complicated with heart failure. Methods Seventy patients with severe pneumonia complicated with heart failure hospitalized in our hospital from April 2009 to May 2012 were selected and divided into observation group and control group with 35 cases each. The control group received routine treatment. The observation group was given phentolamine and angiotensin-converting enzyme inhibitor captopril on the basis of the control group. The clinical efficacy of the two groups were compared. Results The total effective rate in observation group was 91.4% after 24 hours, which was higher than that in control group (80.0%), the difference was statistically significant (P <0.05). The correction time, symptom relief time, Disappearance time and total length of hospital stay were significantly shorter than those in the control group (P <0.05). Conclusion Phentolamine combined with ACEI in the treatment of infantile severe pneumonia complicated with heart failure has a significant effect, the improvement of heart failure symptoms in children is worthy of clinical promotion.